Barclays
RARE icon

Barclays’s Ultragenyx Pharmaceutical RARE Stock Holding History

Barclays’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$150K Buy
+10,000
New +$240K ﹤0.01% 4127
2025
Q2 		– Sell
-12,500
Closed -$453K – 5483
2025
Q1 		$453K Buy
+12,500
New +$520K ﹤0.01% 3593
2024
Q2 		– Sell
-30,000
Closed -$1.4M – 5217
2024
Q1 		$1.4M Hold
30,000
– – ﹤0.01% 2863
2023
Q4 		$1.43M Buy
+30,000
New +$1.16M ﹤0.01% 3173
2019
Q2 		– Sell
-600
Closed -$42K – 7209
2019
Q1 		$42K Hold
600
– – ﹤0.01% 6003
2018
Q4 		$26K Buy
+600
New +$32.8K ﹤0.01% 5782
2017
Q4 		– Sell
-100
Closed -$5K – 7073
2017
Q3 		$5K Sell
100
-400
-80% -$23.7K ﹤0.01% 6423
2017
Q2 		$31K Hold
500
– – ﹤0.01% 5594
2017
Q1 		$34K Buy
+500
New +$38.1K ﹤0.01% 5551
2015
Q3 		– Sell
-25,000
Closed -$2.55M – 7004
2015
Q2 		$2.55M Buy
+25,000
New +$1.94M ﹤0.01% 2027

Other funds holding RARE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's RARE Position: Q3 2026 in Review

Barclays increased its Ultragenyx Pharmaceutical (RARE) stake by 282% in Q3 2026, buying an estimated $10.5M and bringing the position to 591,805 shares worth $8.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Barclays first reported a position in RARE in Q1 2014 and has held it in 51 quarters since. The position peaked at $12.8M in Q3 2025. 183 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Barclays held 591,805 shares of Ultragenyx Pharmaceutical worth $8.89M as of Q3 2026.
  • Barclays bought 436,929 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $10.5M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1709 holding.
  • Barclays first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 51 quarters since.
  • Barclays's Ultragenyx Pharmaceutical position peaked at $12.8M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.